Overview: CHMP’s January 2026 decision highlights The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded its January 2026 session by recommending six medicines for marketing authorization in the European Union. This marks a significant moment for patients awaiting new therapies, as well as for the biotech and pharmaceutical industries focused on…